Loading company…
Rongmei Bio develops drug candidates for neurodegenerative and lysosomal diseases.
Rongmei Bio conducts drug discovery, target validation, and translational research focused on lysosomal ion channels and membrane transport proteins. Its work includes small-molecule design and preclinical evaluation for neurodegenerative disease pathways. Founded in 2023 and based in Hangzhou, China, the company received venture funding from new investor Co-Win Ventures in July 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Zhejiang Rongmei Biopharmaceutical Technology Co., Ltd.? This is my company